A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo

Endocrinology

Volumn 151, Issue 12, 2010, Pages 5905-5915

  Garside, Samantha A ^a   Henkin, Jack ^b   Morris, Keith D ^a   Norvell, Suzanne M ^b   Thomas, Fiona H ^a   Fraser, Hamish M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 898; PLASMA PROTEIN; PROGESTERONE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GRANULOSA CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUTEOLYSIS; MARMOSET; NONHUMAN; OVARY FOLLICLE ATRESIA; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RAT;

ANIMALS; CALLITHRIX; CELLS, CULTURED; FEMALE; FOLLICULAR ATRESIA; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES; OVARIAN FOLLICLE; RATS; RATS, WISTAR; THROMBOSPONDINS;

EID: 78649829858     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0283     Document Type: Article

References (63)

1. Folkman J, Klagsbrun M 1987 Angiogenic factors. Science 235:442-447
2. Geva E, Jaffe RB 2000 Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74:429-438
3. Fraser HM 2006 Regulation of the ovarian follicular vasculature. Reprod Biol Endocrinol 4:18
4. Fraser HM, Wilson H, Morris KD, Swanston I, Wiegand SJ 2005 Vascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaque. J Clin Endocrinol Metab 90:5811-5818
5. Stouffer RL, Martínez-Chequer JC, Molskness TA, Xu F, Hazzard TM 2001 Regulation and action of angiogenic factors in the primate ovary. Arch Med Res 32:567-575
6. Fraser HM, Duncan WC 2009 SRB Reproduction, Fertility and Development Award Lecture 2008. Regulation and manipulation of angiogenesis in the ovary and endometrium. Reprod Fertil Dev 21:377-392
7. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM 2002 Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143:2797-2807 (Pubitemid 34701344)
8. Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV, Kitajewski J 2003 Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. J Clin Invest 112:659-669 (Pubitemid 38057707)
9. Folkman J 2004 Endogenous angiogenesis inhibitors. APMIS 112:496-507
10. Folkman J 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286
11. Armstrong LC, Bornstein P 2003 Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22:63-71
12. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N 1993 Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511
13. Danforth DR, Arbogast LK, Ghosh S, Dickerman A, Rofagha R, Friedman CI 2003 Vascular endothelial growth factor stimulates preantral follicle growth in the rat ovary. Biol Reprod 68:1736-1741
14. Lawler J 2002 Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12
15. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J 2007 Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210:807-818 (Pubitemid 46185050)
16. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N 2003 Thrombospondin-1- deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 228:630-642 (Pubitemid 37493982)
17. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, Hynes RO 2001 Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 159:1949-1956
18. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO 1998 Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101:982-992
19. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R 2005 Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 102:2934-2939
20. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML 2001 Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 98:12485-12490
21. Miyanaga K, Kato Y, Nakamura T, Matsumura M, Amaya H, Horiuchi T, Chiba Y, Tanaka K 2002 Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res 22:3941-3948
22. Tanaka K, Sonoo H, Kurebayashi J, Nomura T, Ohkubo S, Yamamoto Y, Yamamoto S 2002 Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin Cancer Res 8:1125-1131
23. Ren B, Yee KO, Lawler J, Khosravi-Far R 2006 Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 1765:178-188
24. Garside SA, Harlow CR, Hillier SG, Fraser HM, Thomas FH 2010 Thrombospondin-1 inhibits angiogenesis and promotes follicular atresia in a novel in vitro angiogenesis assay. Endocrinology 151:1280-1289
25. Agrawal R, Jacobs H, Payne N, Conway G 2002 Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril 78:1164-1169
26. Franks S, Mason H, Willis D 2000 Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol 163:49-52
27. Zhang X, Lawler J 2007 Thrombospondin-based antiangiogenic therapy. Microvasc Res 74:90-99
28. Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, Stewart Jr JE, Gladson CL 2007 ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 6:454-462
29. Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL 2007 Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67:1716-1724
30. Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J 2009 ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 8:64-74
31. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C 2006 Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 12:7444-7455
32. Gietema JA, Hoekstra R, de Vos FY, Uges DR, van der Gaast A, Groen HJ, Loos WJ, Knight RA, Carr RA, Humerickhouse RA, Eskens FA 2006 A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 17:1320-1327
33. Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, Carr RA, Humerickhouse R, Verweij J, Gietema JA 2006 Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 42:467-472
34. Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG 2005 Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1- mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23:5188-5197
35. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET 2007 A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30:303-309
36. Fraser HM, Dickson SE, Morris KD, Erickson GF, Lunn SF 1999 The effect of the angiogenesis inhibitor TNP-470 on luteal establishment and function in the primate. Hum Reprod 14:2054-2060
37. Taylor PD, Wilson H, Hillier SG, Wiegand SJ, Fraser HM 2007 Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset. Mol Hum Reprod 13:729-736
38. Fraser HM, Wulff C 2001 Angiogenesis in the primate ovary. Reprod Fertil Dev 13:557-566
39. Smith KB, Lunn SF, Fraser HM 1990 Inhibin secretion during the ovulatory cycle and pregnancy in the common marmoset monkey. J Endocrinol 126:489-495
40. Gilchrist RB, Wicherek M, Heistermann M, Nayudu PL, Hodges JK 2001 Changes in follicle-stimulating hormone and follicle populations during the ovarian cycle of the common marmoset. Biol Reprod 64:127-135
41. Summers PM, Wennink CJ, Hodges JK 1985 Cloprostenol-induced luteolysis in the marmoset monkey (Callithrix jacchus). J Reprod Fertil 73:133-138
42. A40. J Clin Endocrinol Metab 86:3377-3386
43. Fraser HM, Wilson H, Wulff C, Rudge JS, Wiegand SJ 2006 Administration of vascular endothelial growth factor Trap during the 'post-angiogenic' period of the luteal phase causes rapid functional luteolysis and selective endothelial cell death in the marmoset. Reproduction 132:589-600
44. Thomas FH, Telfer EE, Fraser HM 2007 Expression of anti-Mullerian hormone protein during early follicular development in the primate ovary in vivo is influenced by suppression of gonadotropin secretion and inhibition of vascular endothelial growth factor. Endocrinology 148:2273-2281
45. Byskov AG 1974 Cell kinetic studies of follicular atresia in the mouse ovary. J Reprod Fertil 37:277-285
46. Tamanini C, De Ambrogi M 2004 Angiogenesis in developing follicle and corpus luteum. Reprod Domest Anim 39:206-216
47. Ferrara N 2004 Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611 (Pubitemid 39099316)
48. Petrik JJ, Gentry PA, Feige JJ, LaMarre J 2002 Expression and localization of thrombospondin-1 and -2 and their cell-surface receptor, CD36, during rat follicular development and formation of the corpus luteum. Biol Reprod 67:1522-1531
49. Greenaway J, Gentry PA, Feige JJ, LaMarre J, Petrik JJ 2005 Thrombospondin and vascular endothelial growth factor are cyclically expressed in an inverse pattern during bovine ovarian follicle development. Biol Reprod 72:1071-1078
50. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP 1997 CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707-717
51. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J 2009 Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23:3368-3376
52. Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F, Kandemir B 2009 Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205:854-857
53. Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP 1997 Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 235:403-412
54. Bendeck MP 2004 Macrophage matrix metalloproteinase-9 regulates angiogenesis in ischemic muscle. Circ Res 94:138-139
55. Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, Lehnert H, Randeva HS 2009 Metformin decreases angiogenesis via NF-κB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res 83:566-574
56. Thomas FH, Wilson H, Silvestri A, Fraser HM 2008 Thrombospondin-1 expression is increased during follicular atresia in the primate ovary. Endocrinology 149:185-192
57. Sengupta K, Banerjee S, Saxena NK, Banerjee SK 2004 Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res 2:150-158
58. Sarkar AJ, Chaturvedi K, Chen CP, Sarkar DK 2007 Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors. J Endocrinol 192:395-403
59. Guo N, Krutzsch HC, Inman JK, Roberts DD 1997 Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735-1742
60. Nör JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ 2000 Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37:209-218
61. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N 2000 Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41-48
62. Greenaway J, Connor K, Pedersen HG, Coomber BL, LaMarre J, Petrik J 2004 Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology 145:2896-2905
63. Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, Tan SL, Campbell S, Jacobs HS 1998 Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum Reprod 13:651-655